Universe Pharmaceuticals INC
UPCHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 24, 2026
Scan Results
Daily timeframeUniverse Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. At a $21.8M market cap, Universe Pharmaceuticals INC ranks as a micro-cap company within healthcare. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications.
Market Cap
$21.8M
Beta
1.68
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-1.44
EPS (Fwd)
—
ROE
-3.5%
ROA
-1.7%
Cash
$29.0M
Total Debt
$9.6M
Free CF
-$21.4M
52W Change
-13.2%
Annual Financials
Cash vs Debt
Where UPC stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, UPC finished 5.53% below its 150-day moving average ($3.98) and 2.84% below its 200-day moving average ($3.87). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is UPC overbought or oversold?
At the October 20, 2026 close, UPC's RSI(14) was 26.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Universe Pharmaceuticals INC holds $29.0M in cash against $9.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$21.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -3.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $40.1M (2022) to $17.9M (2025), a 56% decline worth watching.
Universe Pharmaceuticals INC's elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing UPC.